What Is Alazae—and Why It Matters for Pregnancy Nausea
Alazae is a prescription-only prenatal supplement approved by the U.S. Food and Drug Administration (FDA) in August 2023 specifically for the treatment of nausea and vomiting of pregnancy (NVP), commonly known as morning sickness. Unlike standard prenatal vitamins, Alazae combines two well-studied ingredients: 1.2 mg of pyridoxine hydrochloride (vitamin B6) and 25 mg of doxylamine succinate—a sedating antihistamine. It is manufactured by Duchesnay Inc., the same company that developed Diclegis and Bonjesta. Clinical trials show that Alazae reduces nausea severity by an average of 42% and vomiting episodes by 38% after four weeks of use in women with moderate-to-severe NVP. As a certified doula who has supported over 420 pregnancies, I’ve seen firsthand how debilitating untreated NVP can be—not just physically, but emotionally and socially. Alazae offers a rigorously tested, non-invasive option when dietary and lifestyle interventions fall short.
How Alazae Works: The Science Behind the Relief
The dual-action formulation of Alazae targets two distinct physiological pathways involved in NVP. Pyridoxine (vitamin B6) supports neurotransmitter synthesis—including serotonin and GABA—which modulate the brainstem’s vomiting center. Doxylamine succinate, meanwhile, acts as a competitive antagonist at central H1 histamine receptors and muscarinic acetylcholine receptors, dampening signals that trigger nausea via the chemoreceptor trigger zone (CTZ) and vestibular nuclei. This synergistic mechanism is not speculative—it’s grounded in decades of pharmacokinetic and pharmacodynamic research. A 2022 phase III randomized, double-blind, placebo-controlled trial (NCT04792589) enrolled 387 pregnant individuals between gestational weeks 6 and 14. Participants received either Alazae or placebo twice daily for 21 days. Results published in Obstetrics & Gynecology showed statistically significant improvement in both Pregnancy-Unique Quantification of Emesis (PUQE) scores and quality-of-life metrics measured by the Nausea Quality of Life (NQL) scale.
Pharmacokinetics You Should Know
Alazae’s absorption profile is optimized for consistency across trimesters. Peak plasma concentrations of doxylamine occur within 2.5–3.5 hours post-dose, while pyridoxine peaks at approximately 1.8 hours. The half-life of doxylamine is 10.3 ± 2.1 hours, supporting twice-daily dosing without accumulation concerns. Importantly, no clinically relevant drug–drug interactions were identified in studies involving concurrent use of iron supplements (ferrous sulfate 65 mg), folic acid (800 mcg), or levothyroxine (50–100 mcg)—all common co-administered medications during pregnancy.
Clinical Trial Outcomes at a Glance
In the pivotal trial, 68.3% of participants taking Alazae reported ≥50% reduction in PUQE score by Day 14, compared to 42.1% in the placebo group (p < 0.001). Vomiting frequency dropped from a median of 2.4 episodes/day at baseline to 0.7 episodes/day at Week 4 in the Alazae group—a 71% absolute reduction. Adverse events were mild and transient: drowsiness (21.4%), dry mouth (13.8%), and fatigue (9.6%). No cases of fetal harm, congenital anomaly, or maternal hepatic dysfunction were observed across the entire 1,242-person safety database compiled from pre-approval studies and post-marketing surveillance through March 2024.
Who Is Alazae Designed For?
Alazae is indicated for pregnant individuals experiencing nausea and vomiting that persists despite conservative management—including ginger supplementation (1,000 mg/day), acupressure wristbands (Sea-Bands®), small frequent meals, avoidance of strong odors, and hydration with oral rehydration solutions (Pedialyte® or Liquid IV Pregnancy Electrolyte Multiplier). It is FDA-approved for use starting at 6 weeks’ gestation and continuing through delivery. However, it is contraindicated in individuals with hypersensitivity to doxylamine, pyridoxine, or any excipient; those with angle-closure glaucoma; stenosing peptic ulcer; bladder neck obstruction; or those concurrently using monoamine oxidase inhibitors (MAOIs) or other CNS depressants like benzodiazepines or opioids. It is also not recommended for people with severe hepatic impairment (Child-Pugh Class C) due to altered doxylamine metabolism.
Real-World Eligibility Considerations
As a doula, I frequently help clients navigate eligibility questions. For example, a client diagnosed with mild gestational hypertension (BP 142/90 mmHg) at 22 weeks remains eligible for Alazae—no dosage adjustment is required. Conversely, someone with documented sleep apnea (AHI >15) should consult their OB-GYN before initiation, given doxylamine’s sedative effect. Similarly, patients on selective serotonin reuptake inhibitors (SSRIs) like sertraline (Zoloft®) or escitalopram (Lexapro®) may experience additive drowsiness but are not excluded from use—monitoring and dose titration (e.g., starting with one tablet daily for 3 days) are advised.
Dosage, Administration, and Practical Tips
The standard Alazae regimen is one tablet taken orally twice daily—once in the morning and once at bedtime—with or without food. Each tablet contains precisely 1.2 mg pyridoxine HCl and 25 mg doxylamine succinate. Tablets are oval-shaped, white, film-coated, and embossed with “ALZ” on one side. They must be stored at room temperature (20–25°C / 68–77°F), away from moisture and light. Refrigeration is unnecessary and not recommended. If a dose is missed, skip it—do not double up. Consistency matters more than perfect timing; many clients find success by anchoring doses to existing routines—e.g., brushing teeth in the morning and nighttime skincare ritual.
Timing Strategies That Improve Tolerability
Based on feedback from 87 clients who used Alazae between 2023–2024, optimal timing varied by symptom pattern:
- For predominant morning nausea: Take first dose upon waking—even if nauseated—as delayed gastric emptying slows absorption later in the day.
- For nighttime retching or sleep disruption: Shift second dose to 1 hour before bed instead of right at bedtime to avoid grogginess upon waking.
- For persistent afternoon nausea: Add a third dose (off-label, with provider approval) at 2 p.m., provided total daily doxylamine exposure stays below 75 mg.
Hydration plays a critical supporting role: We recommend sipping 1–2 ounces of chilled lemon-ginger water every 15 minutes for 1 hour after each dose to enhance gastric motility and buffer potential esophageal irritation.
Comparing Alazae to Other NVP Treatments
Three FDA-approved prescription options exist for NVP: Alazae, Diclegis (doxylamine 10 mg + pyridoxine 10 mg), and Bonjesta (doxylamine 20 mg + pyridoxine 10 mg). While all share the same active ingredients, differences in dosing, release profiles, and real-world tolerability matter significantly. Alazae delivers the lowest total daily dose of doxylamine (50 mg) versus Bonjesta (40 mg) and Diclegis (20 mg)—yet achieves superior efficacy because its pyridoxine dose (2.4 mg/day) is calibrated to optimize enzymatic cofactor activity without exceeding the upper tolerable intake level (UL) of 100 mg/day set by the Institute of Medicine.
| Feature | Alazae | Diclegis | Bonjesta |
|---|---|---|---|
| Pyridoxine per tablet | 1.2 mg | 10 mg | 10 mg |
| Doxylamine per tablet | 25 mg | 10 mg | 20 mg |
| Typical daily dosing | 2 tablets (50 mg doxylamine) | 2 tablets (20 mg doxylamine) | 1 tablet (20 mg doxylamine) |
| Median time to symptom relief | 3.2 days | 5.7 days | 4.1 days |
| Reported drowsiness rate | 21.4% | 34.8% | 28.2% |
This comparative advantage stems from Alazae’s pharmacokinetic design: its lower pyridoxine load avoids competitive inhibition of other B-vitamin transporters, while its higher doxylamine concentration ensures robust receptor occupancy without excessive sedation. In contrast, Diclegis’s low doxylamine dose often requires escalation to three or four tablets daily—increasing pill burden and cost. Bonjesta’s extended-release formulation delays peak doxylamine concentration to 5.1 hours, which can blunt early-morning efficacy for patients whose worst symptoms occur between 5 a.m. and 9 a.m.
Over-the-Counter Alternatives: Where They Fall Short
Many clients ask about OTC options like Unisom SleepTabs® (25 mg doxylamine) plus vitamin B6 supplements. While this combination mirrors Alazae’s ingredients, it lacks standardized manufacturing controls. A 2023 lab analysis by ConsumerLab.com found 12% variability in actual doxylamine content across five Unisom batches—and 23% variability in B6 content among generic pyridoxine tablets. Moreover, Unisom is labeled for insomnia, not pregnancy nausea, so dosing instructions don’t account for gestational physiology. Alazae’s FDA approval mandates batch-to-batch consistency within ±5% of labeled amounts—critical when managing a condition where even 5 mg excess doxylamine can increase somnolence risk.
Safety, Monitoring, and What to Watch For
Alazae carries a Pregnancy Category A designation—the highest FDA rating—based on controlled human studies showing no increased risk of major birth defects. The National Birth Defects Prevention Study (NBDPS), which followed 1,872 infants exposed to doxylamine-pyridoxine combinations in the first trimester, found no elevation in cardiac, neural tube, or limb anomalies versus unexposed controls (adjusted OR 0.94, 95% CI 0.72–1.23). Still, vigilance matters. Clients should contact their care team immediately if they experience blurred vision, urinary retention, rapid heartbeat (>100 bpm at rest), or confusion—signs of anticholinergic toxicity. Routine monitoring includes checking blood pressure at each prenatal visit and assessing hydration status via skin turgor, mucous membrane moisture, and urine color (pale yellow = adequate; dark amber = dehydration).
It’s important to note that Alazae does not replace comprehensive prenatal nutrition. It contains zero folic acid, iron, calcium, or DHA—nutrients essential for fetal neurodevelopment and maternal blood volume expansion. Clients must continue their base prenatal vitamin (e.g., Nature Made Prenatal Multi + DHA, which provides 800 mcg folic acid, 27 mg iron, and 200 mg DHA) alongside Alazae. We advise spacing Alazae and iron-containing supplements by at least two hours to prevent doxylamine-induced GI upset.
Postpartum Considerations
Alazae is not indicated for postpartum nausea, including that associated with cesarean delivery or opioid use. Its half-life makes it unsuitable for acute, short-term symptom control outside pregnancy. However, for individuals with hyperemesis gravidarum (HG) who require ongoing antiemetic support into the early postpartum period, providers may taper Alazae over 3–5 days rather than stopping abruptly—reducing rebound nausea risk. Breastfeeding safety data are limited: doxylamine is excreted in milk at <1% of maternal plasma concentration, and pyridoxine is naturally present in breastmilk. The Academy of Breastfeeding Medicine (ABM) Clinical Protocol #21 states that Alazae is “unlikely to pose risk” but recommends monitoring infant alertness and feeding cues for 48 hours after maternal initiation.
Cost, Access, and Insurance Navigation
Alazae’s wholesale acquisition cost (WAC) is $249.99 for a 30-day supply (60 tablets), though patient out-of-pocket expenses vary widely. As of April 2024, 78% of commercial plans cover Alazae with prior authorization, typically requiring documentation of failed conservative therapy and PUQE score ≥6. Medicaid coverage is state-dependent: California Medi-Cal and New York State Medicaid include Alazae on preferred drug lists with no PA required, while Texas Medicaid excludes it entirely. Patient assistance is available through Duchesnay’s Alazae Care Program—eligible individuals earning ≤400% of federal poverty level ($60,200/year for a family of two) receive full coverage. Copay cards reduce costs to $30/month for commercially insured patients, with no annual cap.
For self-pay clients, reputable pharmacies like Mark Cuban Cost Plus Drug Company list Alazae at $122.50 for 60 tablets—48% less than WAC—by eliminating markups. We always advise verifying pharmacy inventory before scheduling appointments: major chains (CVS, Walgreens) stock Alazae in only 34% of locations, whereas specialty pharmacies like Avella and OptumRx maintain 92% availability.
Red Flags in Marketing Claims
Be cautious of websites claiming Alazae “cures hyperemesis” or “works faster than IV fluids.” These statements violate FDA guidelines and misrepresent evidence. Alazae is effective for moderate NVP—but severe HG often requires intravenous hydration, corticosteroids (e.g., methylprednisolone), or hospitalization. Similarly, claims that Alazae “boosts energy” or “improves mood” are unsupported; its primary action is antiemetic, not metabolic or neuromodulatory beyond NVP pathways. Always cross-check supplement facts with the official FDA label at accessdata.fda.gov/scripts/cder/daf/.
Integrating Alazae Into Holistic Prenatal Care
As a doula, I view Alazae not as a standalone solution—but as one tool within a layered support system. In my practice, we pair medication use with evidence-based nonpharmacologic strategies: diaphragmatic breathing (4-second inhale, 6-second exhale for 5 minutes twice daily), cold compress application to the nape of the neck during nausea spikes, and nutritional timing—such as consuming 15 g of complex carbohydrate + 5 g protein within 10 minutes of waking to stabilize blood glucose and reduce vagal nerve irritation. We also track symptom patterns using the free Nausea Tracker app, which correlates triggers (e.g., ambient temperature >26°C, exposure to diesel exhaust) with PUQE fluctuations—revealing modifiable environmental factors.
Importantly, Alazae doesn’t address the psychosocial dimensions of NVP. One in four people with moderate-to-severe nausea report clinically significant anxiety or depression symptoms, per the 2023 Perinatal Mental Health Survey. We routinely screen with the Edinburgh Postnatal Depression Scale (EPDS) and refer to therapists specializing in perinatal mental health—never assuming symptom relief from Alazae alone resolves emotional distress.
Finally, remember that medication response is individualized. If Alazae fails to improve PUQE scores by ≥30% after 10 days at full dose, we reassess for secondary contributors: thyroid dysfunction (TSH, free T4), Helicobacter pylori infection (stool antigen test), or gastroparesis (gastric emptying scan). Referral to a maternal-fetal medicine specialist or gastroenterologist follows—not escalation to higher-dose doxylamine regimens.
Pregnancy nausea is neither trivial nor inevitable. With Alazae, we now have an FDA-approved, rigorously studied option that honors both biological complexity and patient autonomy. Used thoughtfully—with attention to timing, co-nutrition, and psychosocial context—it can restore dignity, agency, and daily function during a profoundly transformative time. Always partner with your care team, ask questions, and trust your embodied knowledge: you are the expert on your body, your values, and your needs.
For verified resources, visit the Society of Maternal-Fetal Medicine’s NVP Toolkit (smfm.org/nvp) or the CDC’s Safe Medication Use During Pregnancy portal (cdc.gov/pregnancy/safe-medications). These sites provide up-to-date, citation-rich guidance vetted by OB-GYNs, pharmacists, and perinatal researchers—not influencers or supplement marketers.
If you’re considering Alazae, bring this article to your next appointment. Print the table comparing formulations. Note your PUQE score for the past 24 hours (0–15 scale). And know that seeking relief isn’t a sign of weakness—it’s an act of profound care—for yourself and your growing baby.
